Transitioning From Methadone to Ibogaine

The single most important idea on this page: the two drugs must never overlap. Because methadone is long-acting and ibogaine’s metabolite noribogaine lingers for a day or two, the goal of a transition is to clear methadone before ibogaine is ever considered.

Four stages, in order

1. Screening & baselines. A cardiac work-up (ECG with QT measurement), bloodwork, electrolytes, and liver and kidney function, plus a review of psychiatric history and current medications.

2. Methadone taper. A gradual, clinician-supervised reduction of the methadone dose over weeks to months, pacing withdrawal so it stays manageable and cardiac risk stays low.

3. Washout. A verified interval after the last methadone dose, during which teams track withdrawal, blood pressure, heart rate and ECG until residual opioid levels and vitals are stable.

4. Monitored dosing & aftercare. Only then, in a supervised setting, is ibogaine considered — followed immediately by structured aftercare. See post-treatment care.

The pharmacology, in plain terms

Methadone fully activates opioid receptors and clears slowly; ibogaine and noribogaine engage opioid and other receptors while also affecting cardiac conduction. If their windows overlap, the combined load on the heart and respiratory system rises. Clinically oriented comparisons such as how ibogaine and methadone detox differ in practice spell out why the timelines and monitoring differ so much between the two approaches.

Not everyone is a candidate

Structural heart disease, a prolonged baseline QT interval, uncontrolled psychiatric conditions or active polysubstance use may rule ibogaine out entirely. Honest disclosure during screening is a safety measure. For many people, harm-reduction logic favours staying on methadone maintenance when the benefits outweigh the risks of switching.

Keep reading